Clinical trials: Patients With Speech Disorders
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Tracheostomy, Communication
A Speech Recognition Application as a Communication Aid for Acute and Critical Care Patients With Tracheostomies
Patients in acute and critical care often undergo a tracheostomy. A tracheostomy is an incision at the front of the neck to insert a breathing tube directly into the airway.
- Conditions
- Tracheostomy, Communication, Acute/Critical Illness
- Trial name
- SRAVI (NCT06027866)
- Testing
- SRAVI (Speech Recognition Application for the Voice Impaired)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Queen's University, Belfast
Aphasia
TMS in Aphasia Recovery
Stroke often causes substantial problems in speaking or understanding speech. Treatments for these problems are currently very limited.
- Trial name
- NCT04777214
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pennsylvania
Parkinson's Disease
Evaluation of Intensive Language Therapy
Due to Parkinson's Disease (PD) speech and language (SL) deficits may occur. Further, the literature reports that PD patients, who have not undergone deep brain stimulation (DBS), have deficits regarding voice quality (e.g.
- Trial name
- EILT (NCT02935842)
- Testing
- Specific SL-therapy, Rhythmic Balance-Movement Training (rBMT)
- Where
- Switzerland
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Respiratory Failure, Speech
Early Speech With One-Way Speaking Valve in Tracheostomy Patients
Patients with tracheostomy who are on and off of mechanical ventilation initially lose the ability to speak, and the use of one-way speaking valves (OWSV) is one method of restoring speech in these patients.
- Conditions
- Respiratory Failure, Speech, Aphonia
- Trial name
- NCT03008174
- Testing
- Early one-way speaking valve (OWSV) assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Glial Tumor
Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy
Patients with brain tumours experience a loss of independence, which may occur suddenly or gradually. Communication with the patient may be rapidly impaired, due to impaired alertness, language and/or neurocognitive disorders.
- Trial name
- SOPHNEURO (NCT05189366)
- Testing
- Sophrology, Speech therapy
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Institut Cancerologie de l'Ouest
Alzheimer's Disease, Aphasia
Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease
The investigators wish to investigate the efficacy of targeted repetitive transcranial magnetic stimulation (rTMS) on expressive language in patients with Alzheimer's disease (AD).
- Conditions
- Alzheimer's Disease, Aphasia, Dementia
- Trial name
- NCT00814697
- Testing
- Repetitive Transcranial Magnetic Coil Stimulation (rTMS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The New York Memory Services
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Meniere's Disease
SPI-1005 for the Treatment of Patients With Meniere's Disease
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
- Trial name
- NCT03325790
- Testing
- 200mg SPI-1005 BID, 400mg SPI-1005 BID
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sound Pharmaceuticals, Incorporated